CN103910781B - A kind of A beta peptide aggregation inhibitor - Google Patents
A kind of A beta peptide aggregation inhibitor Download PDFInfo
- Publication number
- CN103910781B CN103910781B CN201410100093.5A CN201410100093A CN103910781B CN 103910781 B CN103910781 B CN 103910781B CN 201410100093 A CN201410100093 A CN 201410100093A CN 103910781 B CN103910781 B CN 103910781B
- Authority
- CN
- China
- Prior art keywords
- aggregation inhibitor
- beta peptide
- peptide
- peptide aggregation
- beta
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
The invention discloses a kind of A beta peptide aggregation inhibitor, it is characterized in that its aminoacid sequence is: aminoterminal-CTIWYG-carboxyl terminal.This peptide sequence, through afm scan technology for detection, obtains with cytotoxicity experiment evaluation further.It has good restraining effect to the gathering of the major toxicity body-A β causing alzheimer's disease, can attempt being developed as therapeutic agent for alzheimer's disease.
Description
Technical field
The present invention relates to a kind of toxicity body A beta inhibitor of A beta peptide aggregation inhibitor, particularly a kind of anti-Alzheimer disease.
Background technology
At present, the whole world has at least 3,500 ten thousand people to suffer from alzheimer's disease, and annual lethality rate rises.Total cost estimation in the annual whole world reaches 2,000 hundred million dollars, research shows, A β (Amyloid β-peptide) oligomer is the remarkable toxicity body in senile dementia patient body, therefore suppresses the generation of A beta oligomers to be stop senile dementia that the most effective strategy occurs.But, current without effective ways be used for A beta inhibitor design, the main serious challenge in the face of three aspects: 1, lack effective high-throughput screening method: the synthesis of experiment screening method needs and purifying A β, this screening for large quantization compound is time-consuming beyond doubt, expensive and unrealistic.2, lack the high resolution structures of A beta oligomers: A beta oligomers is metastable state, therefore utilize X-ray diffraction and NMR technology to be difficult to obtain its structure, make the Rational drug design of structure based be difficult to realize.3, the understanding to A β self-assembly mechanism is lacked: which part comprising peptide is formed in amyloid fiber generative process plays keying action; Seed generates relevant path with fiber and what intermediate is; Whether A β is affine to specific acceptor; What the mechanism how A β generates toxicity body and toxicity is.Therefore, design new A beta inhibitor, to senile dementia Diagnosis and Treat, there is important practice significance.
Summary of the invention
In view of this, in order to solve the problem, the invention provides a kind of A beta peptide aggregation inhibitor, its aminoacid sequence is: aminoterminal-CTIWYG-carboxyl terminal, can attempt being developed as anti-Alzheimer disease medicine.
Accompanying drawing explanation
In order to make the object, technical solutions and advantages of the present invention clearly, below in conjunction with accompanying drawing, the present invention is described in further detail, wherein:
Fig. 1 is that new designed peptide CTIWYG is to the inhibiting afm scan result of A β.
Embodiment
1) peptide is to the inhibiting afm scan experiment of A β;
By single beam silicon cantilever probe, measure under tapping-mode (TappingMode) pattern, at least scan 4 regions to guarantee that structure is correctly sampled.Fig. 1 be new designed peptide CTIWYG to the inhibiting afm scan result of A β, can find out, through 2 days, CTIWYG had obvious restraining effect to A β.This peptide can be used as A beta peptide aggregation inhibitor, and its sequence is: aminoterminal-CTIWYG-carboxyl terminal.
Fig. 1 new designed peptide CTIWYG to the inhibiting afm scan result of A β (Tapping pattern, A is control experiment (unrestraint agent), and the concentration of A β is 1 μm, in B, the concentration of A β is 20 μMs, the concentration of six peptides is 50 μMs, deposits 2 days, 37 DEG C).
E) cell toxicity test;
Carry out green fluorescent label with Polyanionicdyecalcein to viable cell, and measure its activity, ethidium-1 dyeing carries out red fluorescence mark to dead cell.Relative to the cell inactivation caused by A β, after adding CTIWYG and freshly prepd A β and cell co-culture, corresponding death and viable cells rate are 0.412, can reduce apoptosis significantly relative to the control experiment not adding peptide.After peptide mixes with cell with the A β solution deposited 24 hours, obtaining dead and viable cell ratio is after testing 0.780.
The foregoing is only the preferred embodiments of the present invention, be not limited to the present invention, obviously, those skilled in the art can carry out various change and modification to the present invention and not depart from the spirit and scope of the present invention.Like this, if these amendments of the present invention and modification belong within the scope of the claims in the present invention and equivalent technologies thereof, then the present invention is also intended to comprise these change and modification.
<110> University Of Chongqing
<120> A beta peptide aggregation inhibitor
<140>
<141>
<160>1
<210>1
<211>6
<212>PRT
<213> artificial sequence
<220>
<223>
<400>1
CysThrIlePheTyrGly
15
Claims (1)
1. an A beta peptide aggregation inhibitor, is characterized in that its aminoacid sequence is: aminoterminal-CTIWYG-carboxyl terminal.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410100093.5A CN103910781B (en) | 2014-03-18 | 2014-03-18 | A kind of A beta peptide aggregation inhibitor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410100093.5A CN103910781B (en) | 2014-03-18 | 2014-03-18 | A kind of A beta peptide aggregation inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103910781A CN103910781A (en) | 2014-07-09 |
| CN103910781B true CN103910781B (en) | 2016-02-17 |
Family
ID=51036828
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410100093.5A Expired - Fee Related CN103910781B (en) | 2014-03-18 | 2014-03-18 | A kind of A beta peptide aggregation inhibitor |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103910781B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108676065A (en) * | 2018-05-24 | 2018-10-19 | 华南理工大学 | The tetrapeptide of anti-aβ protein aggregation a kind of and its application and the gene for encoding the tetrapeptide |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009131975A1 (en) * | 2008-04-22 | 2009-10-29 | Schering Corporation | Phenyl-substituted 2-imino-3-methyl pyrrolo pyrimidinone compounds as bace-1 inhibitors, compositions, and their use |
| WO2010098487A1 (en) * | 2009-02-26 | 2010-09-02 | Eisai R&D Management Co., Ltd. | Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors |
| WO2011044181A1 (en) * | 2009-10-08 | 2011-04-14 | Schering Corporation | Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
| CN102180947A (en) * | 2011-02-25 | 2011-09-14 | 重庆大学 | A beta aggregation inhibitor |
| CN102218055A (en) * | 2010-08-31 | 2011-10-19 | 南京大学医学院附属鼓楼医院 | Medicament for treating Alzheimer disease(AD) |
| CN102516359A (en) * | 2011-12-08 | 2012-06-27 | 重庆大学 | Novel anti-senile dementia lead compound |
| CN102675419A (en) * | 2011-03-16 | 2012-09-19 | 上海博智生物科技有限公司 | Abeta oligopeptide polymerization inhibitor and preparation and application thereof |
-
2014
- 2014-03-18 CN CN201410100093.5A patent/CN103910781B/en not_active Expired - Fee Related
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009131975A1 (en) * | 2008-04-22 | 2009-10-29 | Schering Corporation | Phenyl-substituted 2-imino-3-methyl pyrrolo pyrimidinone compounds as bace-1 inhibitors, compositions, and their use |
| WO2010098487A1 (en) * | 2009-02-26 | 2010-09-02 | Eisai R&D Management Co., Ltd. | Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors |
| WO2011044181A1 (en) * | 2009-10-08 | 2011-04-14 | Schering Corporation | Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
| CN102218055A (en) * | 2010-08-31 | 2011-10-19 | 南京大学医学院附属鼓楼医院 | Medicament for treating Alzheimer disease(AD) |
| CN102180947A (en) * | 2011-02-25 | 2011-09-14 | 重庆大学 | A beta aggregation inhibitor |
| CN102675419A (en) * | 2011-03-16 | 2012-09-19 | 上海博智生物科技有限公司 | Abeta oligopeptide polymerization inhibitor and preparation and application thereof |
| CN102516359A (en) * | 2011-12-08 | 2012-06-27 | 重庆大学 | Novel anti-senile dementia lead compound |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103910781A (en) | 2014-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Nie et al. | Quantum sensing of free radicals in primary human dendritic cells | |
| Krstic et al. | Long-range distance measurements on nucleic acids in cells by pulsed EPR spectroscopy | |
| Bousejra-ElGarah et al. | Iron (II) binding to amyloid-β, the Alzheimer’s peptide | |
| Cavallari et al. | Metabolic Studies of Tumor Cells Using [1‐13C] Pyruvate Hyperpolarized by Means of PHIP‐Side Arm Hydrogenation | |
| Bobylev et al. | Fullerenolates: metallated polyhydroxylated fullerenes with potent anti-amyloid activity | |
| Luo et al. | Emodin inhibits human sperm functions by reducing sperm [Ca2+] i and tyrosine phosphorylation | |
| Hu et al. | Blockade of acid-sensing ion channels protects articular chondrocytes from acid-induced apoptotic injury | |
| CN101505802A (en) | Imaging medium comprising lactate and hyperpolarised 13C-pyruvate | |
| ES2381380T3 (en) | 13C-RM imaging or cell death spectroscopy | |
| CN105237628B (en) | A kind of polypeptide for treating alzheimer's disease | |
| Kubíček et al. | Towards MRI contrast agents responsive to Ca (II) and Mg (II) ions: Metal‐induced oligomerization of dota–bisphosphonate conjugates | |
| Ding et al. | Rapidly Signal‐enhanced Metabolites for Atomic Scale Monitoring of Living Cells with Magnetic Resonance | |
| CN103910781B (en) | A kind of A beta peptide aggregation inhibitor | |
| CN103992379B (en) | A kind of A beta peptide aggregation inhibitor | |
| Feng et al. | Static magnetic fields reduce oxidative stress to improve wound healing and alleviate diabetic complications | |
| CN103910782B (en) | A kind of A beta peptide aggregation inhibitor | |
| Chen et al. | Hydrogenated germanene nanosheets as an antioxidative defense agent for acute kidney injury treatment | |
| Lee et al. | n-Butylidenephthalide modulates autophagy to ameliorate neuropathological progress of spinocerebellar ataxia type 3 through mTOR pathway | |
| CN103992380B (en) | A kind of A beta peptide aggregation inhibitor | |
| Bu et al. | Cocrystallization-driven self-assembly with vanillic acid offers a new opportunity for surmounting fast and excessive absorption issues of antifungal drug 5-fluorocytosine: a combined theoretical and experimental research | |
| CN103449477A (en) | Novel nanometer material contrast agent and application thereof | |
| US8933118B2 (en) | Anti-brain-tumor drug | |
| CN102516359B (en) | Anti-senile dementia lead compound | |
| CN108272791A (en) | Application of the fisetin in preparing the drug for inhibiting the aggregation of Tau abnormal proteins | |
| Karachaliou et al. | Neuroprotective Action of Humanin and Humanin Analogues: Research Findings and Perspectives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160217 Termination date: 20170318 |